In 2014, no major breakthroughs were made in understanding the biology of breast cancer or its management; few novel practice-changing studies were presented or published. Nevertheless, important negative results from studies that challenge some of the current concepts, particularly in drug development, underline 2014 as a year of 'failed surrogates and precocious expectations'.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164–172 (2014).
Piccart-Gebhart, M. J. et al. First results from the phase III ALTTO trial (BIG 2–06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA4 (2014).
Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 25, 2357–2362 (2014).
Swain, S. et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (d) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract]. Ann. Oncol. 25 (Suppl. 4), 3500_PR (2014).
Baselga, J. et al. A phase III randomized, double-blind, trial comparing sorafinib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE) [abstract]. Ann. Oncol. 25 (Suppl. 4), LBA8 (2014).
André, F. et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 15, 267–274 (2014).
Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 371, 107–118 (2014).
Moore, H. C. F. et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analogue during chemotherapy (CT) to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international Intergroup trial of SWOG, IBCSG, ECOG, and CALGB (Alliance). J. Clin. Oncol. 32 (Suppl.), LBA505 (2014).
Cardoso, F. et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23, 489–502 (2014); Ann. Oncol. 25, 1871–1888 (2014) (simultaneous publication).
American Society of Clinical Oncology. Breast Cancer Guidelines [online], (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F.C. serves as a consultant and receives honoraria from Astella, AstraZeneca, BV, Celgene, Daiichi Sankyo, Eisai, GE oncology, Genentech/Roche, GlaxoSmithKline, Merck-Sharp Dohme, Merus, Novartis, Pfizer, Prime Oncology, Sanofi. E.S is an advisory board member of AstraZeneca, Genentech/Roche, GlaxoSmithKline and Teva; E.S. receives travel support from Amgen, Novartis and Genentech/Roche, and is speaker's bureau for AstraZeneca, Genentech/Roche and GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Cardoso, F., Senkus, E. A call back to reality!. Nat Rev Clin Oncol 12, 67–68 (2015). https://doi.org/10.1038/nrclinonc.2014.226
Published:
Issue date:
DOI: https://doi.org/10.1038/nrclinonc.2014.226
This article is cited by
-
Advancing Immunotherapy in Metastatic Breast Cancer
Current Treatment Options in Oncology (2017)
